AUR-AFUG-TTM1-A-1-1-R-A743-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AE5G-TTP1-A-1-1-R-A742-41 | — | C | 0.864 |
| 2 | MDT-AP-0118 | Med | Medulloblastoma | 0.838 |
| 3 | MDT-AP-2390 | Med | Medulloblastoma | 0.836 |
| 4 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.818 |
| 5 | MDT-AP-2377 | Med | Medulloblastoma | 0.811 |
| 6 | TCGA-60-2725-01A-01R-1201-07 | — | cohortSQ1 | 0.810 |
| 7 | SRR934877 | — | — | 0.809 |
| 8 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.806 |
| 9 | MBCProject_0734_T1B_RNA | — | C | 0.804 |
| 10 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |